Drug developers are using surrogate endpoints to monitor the effectiveness of immunotherapies, taking into account the differences between immunotherapy and traditional treatments.
Chris Smyth, PhD
Advertisement
Articles by Chris Smyth, PhD
Gene-editing technology has the ability to give oncology researchers an effective treatment option in the fight against cancer. CRISPR-Cas9 is such a technology that is currently being used to study genes in cancer cells.
The smaller biopharmaceutical company perspective on mastering oncology immunotherapy clinical trials.
Advertisement
Latest Updated Articles
Imagining the Impossible: Immunity to CancerPublished: April 1st 2016 | Updated:
- Harnessing CRISPR-Cas9 within Oncology Clinical Research
Published: September 29th 2016 | Updated:
- Developing New Clinical Endpoints for Immuno-Oncology Studies
Published: February 23rd 2017 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
NIH Implements Contingency Plan as Government Shutdown Impacts Research Funding
2
2025 SCRS Global Site Solutions Summit: How Technology Vendors Can Reduce Site Burden and Improve Trial Execution
3
2025 SCRS Global Site Solutions Summit: How to Streamline Site Qualification and Initiation Training
4
AI Everywhere: Architecting the Future of Clinical Trials
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
